Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617,...

RecursionPharma's profile picture

Recursion

17,265 subscribers

11,887 Aufrufe • vor 1 Jahr •via X (Twitter)

Wissenschaft & Technologie
LIVE

Anya Rossi• Live Now

Private livecam show

1 Kommentare

Profilbild von Squeeze Kid
Squeeze Kidvor 1 Jahr

@AACR @afterhourbot hunt REC 617

Ähnliche Videos

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track. 🚀 Key proof points include: ▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date. ▪️ REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile with a reversible mechanism and shorter predicted half-life aimed at reducing on-target platelet toxicity, supporting differentiation in solid tumors and AML. ▪️ REC-4881 (MEK1/2 inhibitor): Strong Phase 2 efficacy signals and a safety profile consistent with the MEK inhibitor class, with FDA engagement initiated to define a potential registrational pathway and an update expected in 2H26. ▪️ Our joint programs with Sanofi continue advancing towards development candidate designation and earlier stage program milestones in the next 12 months, and we expect to continue to translate biological insights from maps delivered to Roche and Genentech into potential target validation milestones over the next 12 months. As CEO and President Najat Khan says, this “represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This progress reflects the strength of both our internal pipeline and partnerships, with multiple differentiated programs advancing through our end-to-end AI platform.” Our Q1 Earnings report also highlights our disciplined capital execution: reiterating the 2026 guidance of <$390M operational cash burn, and supporting runway into early 2028 without additional financing. 👉 Join our Earnings Call on Wed., May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST, here on X and on: ▪️ YouTube: ▪️ LinkedIn: 👉 Analysts, investors, and the public can submit questions here: 👉 Read the full report:
0:25

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track. 🚀 Key proof points include: ▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date. ▪️ REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile with a reversible mechanism and shorter predicted half-life aimed at reducing on-target platelet toxicity, supporting differentiation in solid tumors and AML. ▪️ REC-4881 (MEK1/2 inhibitor): Strong Phase 2 efficacy signals and a safety profile consistent with the MEK inhibitor class, with FDA engagement initiated to define a potential registrational pathway and an update expected in 2H26. ▪️ Our joint programs with Sanofi continue advancing towards development candidate designation and earlier stage program milestones in the next 12 months, and we expect to continue to translate biological insights from maps delivered to Roche and Genentech into potential target validation milestones over the next 12 months. As CEO and President Najat Khan says, this “represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This progress reflects the strength of both our internal pipeline and partnerships, with multiple differentiated programs advancing through our end-to-end AI platform.” Our Q1 Earnings report also highlights our disciplined capital execution: reiterating the 2026 guidance of <$390M operational cash burn, and supporting runway into early 2028 without additional financing. 👉 Join our Earnings Call on Wed., May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST, here on X and on: ▪️ YouTube: ▪️ LinkedIn: 👉 Analysts, investors, and the public can submit questions here: 👉 Read the full report:

Recursion

23,615 Aufrufe • vor 3 Monaten

After a year of intensive research, Dr. William Makis presents the most crucial graph of his career: the ivermectin dosing schedule for cancer. Dr. Makis recommends a starting dose of 1mg per kg of body weight per day for most cancers, including breast, colon, lung, pancreatic, renal, gastric, and leukemias. For a 60kg individual, this translates to 60mg daily, which can be taken as: - Five 12mg pills - Or 6ml of liquid (approximately one teaspoon plus 1ml) The evidence supporting the efficacy of ivermectin is compelling and dose-dependent. - Dr. Shankara Chetty observed a significant drop in a prostate cancer patient’s PSA from 89 to 11 after taking 45mg/day. - Dr. Tess Lawry’s case study showed a remarkable decrease in CA125 (an ovarian cancer marker) from 288 to 22 after just 0.2mg/kg. - A long-term Castro study on children with leukemia demonstrated no side effects after 6 months at a dose of 1mg/kg. For aggressive cancers like pancreatic and brain cancers, a higher dose may be necessary due to the blood-brain barrier. Dr. Makis cites examples: - Dr. Landrito’s colleague with terminal gallbladder cancer experienced the disappearance of cancer after 14 months at a dose of 2mg/kg/day. - The highest documented dose is 2.5mg/kg, as reported by Dr. Chetty, with only transient visual side effects that resolved. Mainstream oncology is unlikely to offer this treatment due to ivermectin’s generic, off-patent status and unprofitable nature. Consequently, there are no funded clinical trials. Dr. Makis concludes that using ivermectin in cancer treatment is straightforward and highly safe. He strongly suggests that those struggling with cancer should start with a dose of 1mg/kg/day. This can be taken for several months, even over a year, with an excellent safety profile based on long-term anecdotal evidence. The power to fight cancer may already be within your reach.
5:47

After a year of intensive research, Dr. William Makis presents the most crucial graph of his career: the ivermectin dosing schedule for cancer. Dr. Makis recommends a starting dose of 1mg per kg of body weight per day for most cancers, including breast, colon, lung, pancreatic, renal, gastric, and leukemias. For a 60kg individual, this translates to 60mg daily, which can be taken as: - Five 12mg pills - Or 6ml of liquid (approximately one teaspoon plus 1ml) The evidence supporting the efficacy of ivermectin is compelling and dose-dependent. - Dr. Shankara Chetty observed a significant drop in a prostate cancer patient’s PSA from 89 to 11 after taking 45mg/day. - Dr. Tess Lawry’s case study showed a remarkable decrease in CA125 (an ovarian cancer marker) from 288 to 22 after just 0.2mg/kg. - A long-term Castro study on children with leukemia demonstrated no side effects after 6 months at a dose of 1mg/kg. For aggressive cancers like pancreatic and brain cancers, a higher dose may be necessary due to the blood-brain barrier. Dr. Makis cites examples: - Dr. Landrito’s colleague with terminal gallbladder cancer experienced the disappearance of cancer after 14 months at a dose of 2mg/kg/day. - The highest documented dose is 2.5mg/kg, as reported by Dr. Chetty, with only transient visual side effects that resolved. Mainstream oncology is unlikely to offer this treatment due to ivermectin’s generic, off-patent status and unprofitable nature. Consequently, there are no funded clinical trials. Dr. Makis concludes that using ivermectin in cancer treatment is straightforward and highly safe. He strongly suggests that those struggling with cancer should start with a dose of 1mg/kg/day. This can be taken for several months, even over a year, with an excellent safety profile based on long-term anecdotal evidence. The power to fight cancer may already be within your reach.

Commentary | Global Ivermectin Research Hub

101,825 Aufrufe • vor 4 Monaten

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:
1:29

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:

Recursion

255,879 Aufrufe • vor 7 Monaten

Today, Recursion reported our 4Q/FY25 business updates and financial results. As CEO and President Najat Khan said, “Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value.” This includes: 🚀 A 5th milestone with Sanofi for a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space. This brings the total upfront and progress-based milestones to $134 million to date. Five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🚀 The first AI-enabled clinical validation of the Recursion OS platform in our FAP program, demonstrating translation from AI-driven biological insight to meaningful patient outcomes. We also have multiple clinical and preclinical programs advancing with defined milestones. 🚀 New preclinical efficacy data for REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability over current inhibitors and is currently in IND-enabling studies. 🚀 $754 million of cash and cash equivalents. We exceeded our original cost savings guidance and now expect runway into early 2028, without additional financing. 👉 Read the full business updates here: 🔹 Tune in to our Earnings Call today, February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, here on X, or on: ▪️ YouTube: ▪️ LinkedIn:
0:24

Today, Recursion reported our 4Q/FY25 business updates and financial results. As CEO and President Najat Khan said, “Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value.” This includes: 🚀 A 5th milestone with Sanofi for a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space. This brings the total upfront and progress-based milestones to $134 million to date. Five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🚀 The first AI-enabled clinical validation of the Recursion OS platform in our FAP program, demonstrating translation from AI-driven biological insight to meaningful patient outcomes. We also have multiple clinical and preclinical programs advancing with defined milestones. 🚀 New preclinical efficacy data for REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability over current inhibitors and is currently in IND-enabling studies. 🚀 $754 million of cash and cash equivalents. We exceeded our original cost savings guidance and now expect runway into early 2028, without additional financing. 👉 Read the full business updates here: 🔹 Tune in to our Earnings Call today, February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, here on X, or on: ▪️ YouTube: ▪️ LinkedIn:

Recursion

11,878 Aufrufe • vor 5 Monaten

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:
0:59

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:

PureTech

10,892 Aufrufe • vor 1 Jahr

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:
2:23

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:

Recursion

11,944 Aufrufe • vor 6 Monaten

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:
1:29

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:

Breakthrough T1D

42,494 Aufrufe • vor 1 Jahr

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO
1:00

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

Dana-Farber

53,991 Aufrufe • vor 2 Monaten

Positioning of drugs in Crohn's disease ___ 1. Start effective therapy early This means at diagnosis in the vast majority of patients. Don’t make patients earn their way onto an effective drug. And use your best drug first. Please do not “save it in case you need it later”. ___ 2. Which of our effective therapies should you start? This matters less that just starting. Think holistically with a patient-centered approach. Age, co-morbidities, extra-intestinal manifestations, pregnancy, etc all important. Consider efficacy - speed of onset, mucosal healing, durability of remission - and safety. Mode of delivery - intravenous, subcutaneous, oral - is important. But comes after patient factors, efficacy and safety. Access issues will predominate for many. Use what you have. Use what you know. Just use an effective drug. ___ 3. Use a treat-to-target approach Without labouring the points around STRIDE-2, I’ll put it very simply: - monitor, monitor, monitor act on the results of the monitoring. Don’t keep going with a therapy that isn’t working. ___ 4. Know when to dose optimise versus switch Optimising anti-TNF is often a good ploy. But do it properly and don’t wait too long. Double the dose, shorten the frequency and wait 2-3 cycles. If it isn’t working then (objectively), switch out of class. With ustekinumab, I would no longer dose optimise, but rather switch a partial responder to risankizumab. ___ 5. Active disease is more dangerous than any drugs Two bits of data this year show this: i) In Profile, patients in the step-up group had twice as many adverse events as those in the top-down group. Most of this was because of flaring Crohn’s disease - including hospitalisations for severe disease - but there were also fewer serious infections in the top down group. And that was with combination infliximab and azathioprine. ii) Two meta-analyses of the harms from placebo in RCT’s show a very clear signal. Active Crohn’s disease and UC, when left untreated for even a number of week, is associated with increased toxicity. More on this later. ___ 6. Avoid steroids The majority of patients with Crohn’s disease can be managed effectively now without steroids. They will still have a role in sick patients, to bridge to some therapies, and a course of budesonide in mild to moderate ileal Crohn’s disease is often useful. However we have better strategies now, including using JAK inhibitors in place of steroids. We are increasingly using a short course to (re)capture response to a biologic or keeping the JAKi going in combination at a low dose. ___ 7. Other treatment modalities Surgery and nutritional therapy are particularly important. ___ 8. Changing the natural history of Crohn’s disease Disease modification is the end result when following these principles. We see it in the Edinburgh IBD clinic. A decade since we switched to a top-down strategy for Crohn’s disease and our patients have better disease control, less surgery and fewer hospitalisations. Clearly we still have work to do, but this is major progress.
4:55

Positioning of drugs in Crohn's disease ___ 1. Start effective therapy early This means at diagnosis in the vast majority of patients. Don’t make patients earn their way onto an effective drug. And use your best drug first. Please do not “save it in case you need it later”. ___ 2. Which of our effective therapies should you start? This matters less that just starting. Think holistically with a patient-centered approach. Age, co-morbidities, extra-intestinal manifestations, pregnancy, etc all important. Consider efficacy - speed of onset, mucosal healing, durability of remission - and safety. Mode of delivery - intravenous, subcutaneous, oral - is important. But comes after patient factors, efficacy and safety. Access issues will predominate for many. Use what you have. Use what you know. Just use an effective drug. ___ 3. Use a treat-to-target approach Without labouring the points around STRIDE-2, I’ll put it very simply: - monitor, monitor, monitor act on the results of the monitoring. Don’t keep going with a therapy that isn’t working. ___ 4. Know when to dose optimise versus switch Optimising anti-TNF is often a good ploy. But do it properly and don’t wait too long. Double the dose, shorten the frequency and wait 2-3 cycles. If it isn’t working then (objectively), switch out of class. With ustekinumab, I would no longer dose optimise, but rather switch a partial responder to risankizumab. ___ 5. Active disease is more dangerous than any drugs Two bits of data this year show this: i) In Profile, patients in the step-up group had twice as many adverse events as those in the top-down group. Most of this was because of flaring Crohn’s disease - including hospitalisations for severe disease - but there were also fewer serious infections in the top down group. And that was with combination infliximab and azathioprine. ii) Two meta-analyses of the harms from placebo in RCT’s show a very clear signal. Active Crohn’s disease and UC, when left untreated for even a number of week, is associated with increased toxicity. More on this later. ___ 6. Avoid steroids The majority of patients with Crohn’s disease can be managed effectively now without steroids. They will still have a role in sick patients, to bridge to some therapies, and a course of budesonide in mild to moderate ileal Crohn’s disease is often useful. However we have better strategies now, including using JAK inhibitors in place of steroids. We are increasingly using a short course to (re)capture response to a biologic or keeping the JAKi going in combination at a low dose. ___ 7. Other treatment modalities Surgery and nutritional therapy are particularly important. ___ 8. Changing the natural history of Crohn’s disease Disease modification is the end result when following these principles. We see it in the Edinburgh IBD clinic. A decade since we switched to a top-down strategy for Crohn’s disease and our patients have better disease control, less surgery and fewer hospitalisations. Clearly we still have work to do, but this is major progress.

Charlie Lees

15,650 Aufrufe • vor 1 Jahr

The Pillars of Cancer Treatment Are a Lie. Chemo and Radiation Aren't Just Brutal—They're Actively Destroying Your Natural Killer Cells, the Very Thing Standing Between You and Cancer. A stunning revelation from Dr. Patrick Soon-Shiong that reframes our entire battle against cancer. He shares a truth 460 million years in the making. Within every one of us is an ancient gift, a cell bestowed by the very process of creation: the Natural Killer (NK) cell. Dr. Soon-Shiong explains that this cell is our fundamental biological shield, the key reason humanity has survived infection, trauma, and cancer across millennia. Yet, for decades, modern medicine has waged a devastating war on this very protector. How? With the very pillars of our oncological arsenal: high-dose chemotherapy, radiation, steroid therapy, and even newer modalities. These treatments, while aimed at cancer, systematically destroy the NK cells designed to defend us. A single dose of radiation can obliterate this natural defense for a year, leaving patients vulnerable. Dr. Soon-Shiong presents a paradigm-shattering question: What if, instead of attacking the body’s innate protection, we learned to unlock and unleash it? The answer is here. After a lifetime of research, a method has been discovered and approved to activate the body as its own factory. A single intervention—a “bio-shield”—that proliferates these natural killer cells, empowering them to do what they were designed to do: protect you from cancer. The results? Real patients with bladder cancer, free of disease for a decade. This is not a future promise. This is a present reality, approved in 2024. Dr. Soon-Shiong credits the current administration for its role in moving this breakthrough forward for the entire nation. The era of destroying the body to save it is ending. The era of activating our 460-million-year-old innate defense has begun.
2:58

The Pillars of Cancer Treatment Are a Lie. Chemo and Radiation Aren't Just Brutal—They're Actively Destroying Your Natural Killer Cells, the Very Thing Standing Between You and Cancer. A stunning revelation from Dr. Patrick Soon-Shiong that reframes our entire battle against cancer. He shares a truth 460 million years in the making. Within every one of us is an ancient gift, a cell bestowed by the very process of creation: the Natural Killer (NK) cell. Dr. Soon-Shiong explains that this cell is our fundamental biological shield, the key reason humanity has survived infection, trauma, and cancer across millennia. Yet, for decades, modern medicine has waged a devastating war on this very protector. How? With the very pillars of our oncological arsenal: high-dose chemotherapy, radiation, steroid therapy, and even newer modalities. These treatments, while aimed at cancer, systematically destroy the NK cells designed to defend us. A single dose of radiation can obliterate this natural defense for a year, leaving patients vulnerable. Dr. Soon-Shiong presents a paradigm-shattering question: What if, instead of attacking the body’s innate protection, we learned to unlock and unleash it? The answer is here. After a lifetime of research, a method has been discovered and approved to activate the body as its own factory. A single intervention—a “bio-shield”—that proliferates these natural killer cells, empowering them to do what they were designed to do: protect you from cancer. The results? Real patients with bladder cancer, free of disease for a decade. This is not a future promise. This is a present reality, approved in 2024. Dr. Soon-Shiong credits the current administration for its role in moving this breakthrough forward for the entire nation. The era of destroying the body to save it is ending. The era of activating our 460-million-year-old innate defense has begun.

Camus

150,992 Aufrufe • vor 10 Monaten

Next onto my conversation with Dr. Ashish Kamat Ashish M. Kamat, MD, MBBS and one of the country's leading bladder cancer experts to hear his clinical decision making process as to how he treats patients with BCG unresponsive high-grade papillary disease when no CIS disease is found. (I said the word 'found' since sometimes once high-grade papillary disease is identified, physicians don't bother to look for CIS since their decision making process for treatment is the same if high-grade papillary alone exists. Worse, only 6% of urologists have the blue-light cystoscopy scope that helps them find CIS disease). Dr. Kamat who participated in the initial guidelines discussion with regard to BCG unresponsive in 2016, gave me an insightful answer as to how he treats patients clinically with high-grade papillary alone. Please listen to his insightful answer, the editor of the seminal textbook entitled, "Bladder Cancer: A Practical Guide". He treats patients with high-grade papillary disease alone no differently than in patients with high-grade papillary and CIS disease. This was not surprising for me to hear since he and many others believe that CIS and papillary are the same disease! The next day I attended the FDA workshop in which his fellow colleagues concurred that CIS and papillary was the same disease and also said that they approached patients with BCG unresponsive high-grade papillary disease in the same way as he shared with me in this interview, taken the day before the FDA workshop. His fellow colleagues and experts at the workshop said that they "struggled" and were compelled to make decisions with no option but to prescribe "off-label" therapies for patients who they see (with papillary disease alone) by writing a prescription for already FDA approved therapies for papillary and CIS disease. So the consensus at this panel completely matched the panel of experts from comprehensive cancer centers across the nation who made up the NCCN and provided category 2A status for Anktiva + BCG for the treatment of BCG unresponsive papillary disease alone. Cancer is a war against time Disclaimer: Anktiva + BCG for the treatment of BCG unresponsive papillary disease is not approved and is awaiting review by the FDA as a supplemental BLA. For more details of ANKTIVA + BCG, please refer to our package insert and important safety information. ANKTIVA is approved by the FDA in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. Important Safety Information U.S. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA® at
1:14

Next onto my conversation with Dr. Ashish Kamat Ashish M. Kamat, MD, MBBS and one of the country's leading bladder cancer experts to hear his clinical decision making process as to how he treats patients with BCG unresponsive high-grade papillary disease when no CIS disease is found. (I said the word 'found' since sometimes once high-grade papillary disease is identified, physicians don't bother to look for CIS since their decision making process for treatment is the same if high-grade papillary alone exists. Worse, only 6% of urologists have the blue-light cystoscopy scope that helps them find CIS disease). Dr. Kamat who participated in the initial guidelines discussion with regard to BCG unresponsive in 2016, gave me an insightful answer as to how he treats patients clinically with high-grade papillary alone. Please listen to his insightful answer, the editor of the seminal textbook entitled, "Bladder Cancer: A Practical Guide". He treats patients with high-grade papillary disease alone no differently than in patients with high-grade papillary and CIS disease. This was not surprising for me to hear since he and many others believe that CIS and papillary are the same disease! The next day I attended the FDA workshop in which his fellow colleagues concurred that CIS and papillary was the same disease and also said that they approached patients with BCG unresponsive high-grade papillary disease in the same way as he shared with me in this interview, taken the day before the FDA workshop. His fellow colleagues and experts at the workshop said that they "struggled" and were compelled to make decisions with no option but to prescribe "off-label" therapies for patients who they see (with papillary disease alone) by writing a prescription for already FDA approved therapies for papillary and CIS disease. So the consensus at this panel completely matched the panel of experts from comprehensive cancer centers across the nation who made up the NCCN and provided category 2A status for Anktiva + BCG for the treatment of BCG unresponsive papillary disease alone. Cancer is a war against time Disclaimer: Anktiva + BCG for the treatment of BCG unresponsive papillary disease is not approved and is awaiting review by the FDA as a supplemental BLA. For more details of ANKTIVA + BCG, please refer to our package insert and important safety information. ANKTIVA is approved by the FDA in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. Important Safety Information U.S. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA® at

Dr. Pat Soon-Shiong

21,255 Aufrufe • vor 2 Monaten

Hello, my dear friends, we have some breaking news today! Our rentosertib (novel target that has never been in clinical trials before we picked it using AI, novel molecule designed using true generative AI with the published broadly used AI platform, targeting fibrosis and biology of aging) entered Phase III trial in Idiopathic Pulmonary Fibrosis. This is a major milestone in the life of every drug hunter - the ultimate test. To my knowledge, in our AI drug discovery industry, no other company took the drug for a novel target with a novel molecule into Phase III before so it is a big milestone for the entire industry. Of course, at Insilico we are no longer dependent on this program - we have 13 INDs and many clinical trials are ongoing internally and run by partners. But this program is very special as we also demonstrated the senomorphic properties of this drug and built the entire pipeline of molecules around this target. Please Wish Me Luck! Luck is the most important superpower in everything we do and if we succeed with this program and also demonstrate the antiaging effect - all of us will benefit. Godspeed, my friends and thanks to everyone who helped us along the way!
2:26

Hello, my dear friends, we have some breaking news today! Our rentosertib (novel target that has never been in clinical trials before we picked it using AI, novel molecule designed using true generative AI with the published broadly used AI platform, targeting fibrosis and biology of aging) entered Phase III trial in Idiopathic Pulmonary Fibrosis. This is a major milestone in the life of every drug hunter - the ultimate test. To my knowledge, in our AI drug discovery industry, no other company took the drug for a novel target with a novel molecule into Phase III before so it is a big milestone for the entire industry. Of course, at Insilico we are no longer dependent on this program - we have 13 INDs and many clinical trials are ongoing internally and run by partners. But this program is very special as we also demonstrated the senomorphic properties of this drug and built the entire pipeline of molecules around this target. Please Wish Me Luck! Luck is the most important superpower in everything we do and if we succeed with this program and also demonstrate the antiaging effect - all of us will benefit. Godspeed, my friends and thanks to everyone who helped us along the way!

Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)

49,498 Aufrufe • vor 1 Monat

📣 Solidus Ai Tech Data Center – Weekly Update! This week marked significant advancements at the HPC Data Center site, aligning with our strategic goals of enhancing operational efficiency and sustainability. Here’s an overview of the latest developments: 1. Electrical Systems Finalized: The electrical works have been completed, with high-voltage testing scheduled to commence on Monday. These tests are crucial for ensuring the reliability and safety of the infrastructure. 2. CO2 Fire Suppression System Update: The control panel for the CO2 system has been installed, and the cylinders with gas are expected to arrive next week, bringing us closer to finalizing the fire safety measures. 3. Cabinet Installation Preparation: The server cabinets are prepped for installation. After the high-voltage tests are completed, the cabinets will be moved into the server room, allowing the next phase of the setup to proceed. These updates reinforce our commitment to providing a state-of-the-art, eco-friendly HPC data center that supports diverse industries and advances European technological independence. We’re on track to meet our goals and look forward to sharing more progress in the coming weeks.
0:33

📣 Solidus Ai Tech Data Center – Weekly Update! This week marked significant advancements at the HPC Data Center site, aligning with our strategic goals of enhancing operational efficiency and sustainability. Here’s an overview of the latest developments: 1. Electrical Systems Finalized: The electrical works have been completed, with high-voltage testing scheduled to commence on Monday. These tests are crucial for ensuring the reliability and safety of the infrastructure. 2. CO2 Fire Suppression System Update: The control panel for the CO2 system has been installed, and the cylinders with gas are expected to arrive next week, bringing us closer to finalizing the fire safety measures. 3. Cabinet Installation Preparation: The server cabinets are prepped for installation. After the high-voltage tests are completed, the cabinets will be moved into the server room, allowing the next phase of the setup to proceed. These updates reinforce our commitment to providing a state-of-the-art, eco-friendly HPC data center that supports diverse industries and advances European technological independence. We’re on track to meet our goals and look forward to sharing more progress in the coming weeks.

AITECH CLOUD NETWORK

65,448 Aufrufe • vor 1 Jahr

I am thrilled to share an exhilarating update on Kokoon's ambitious plans and remarkable progress. Our expansion across the United States is moving at lightning speed, and the response has been overwhelmingly positive. People are genuinely excited about Kokoon's innovative medical system, and we are eager to bring our vision to life. We are proud to announce that we will establish a high-end satellite clinic in Beverly Hills, which will serve as a key hub linked to our state-of-the-art medical resort in Miami. Our goal is to ensure accessibility and excellence in healthcare, with plans to open a clinic in every state across the USA and in the ten largest cities in America. These facilities will be seamlessly integrated with our European operations, creating a robust global network. On the corporate front, Kokoon Property Norway ASA has successfully completed the pre-selling phase for its stock, and we are no longer accepting new investors. We are now preparing for a direct listing with Kokoon Global Inc on the New York Stock Exchange, a significant milestone that will enhance our visibility and growth potential. The momentum at Kokoon is unstoppable, and we are committed to delivering unparalleled healthcare solutions with speed and precision. The future is incredibly bright, and we are confident that Kokoon will achieve extraordinary success. Thank you for your continued support and belief in our mission. Stay tuned for more exciting updates as we redefine healthcare on a global scale.
0:37

I am thrilled to share an exhilarating update on Kokoon's ambitious plans and remarkable progress. Our expansion across the United States is moving at lightning speed, and the response has been overwhelmingly positive. People are genuinely excited about Kokoon's innovative medical system, and we are eager to bring our vision to life. We are proud to announce that we will establish a high-end satellite clinic in Beverly Hills, which will serve as a key hub linked to our state-of-the-art medical resort in Miami. Our goal is to ensure accessibility and excellence in healthcare, with plans to open a clinic in every state across the USA and in the ten largest cities in America. These facilities will be seamlessly integrated with our European operations, creating a robust global network. On the corporate front, Kokoon Property Norway ASA has successfully completed the pre-selling phase for its stock, and we are no longer accepting new investors. We are now preparing for a direct listing with Kokoon Global Inc on the New York Stock Exchange, a significant milestone that will enhance our visibility and growth potential. The momentum at Kokoon is unstoppable, and we are committed to delivering unparalleled healthcare solutions with speed and precision. The future is incredibly bright, and we are confident that Kokoon will achieve extraordinary success. Thank you for your continued support and belief in our mission. Stay tuned for more exciting updates as we redefine healthcare on a global scale.

Per Jacob Solli

1,113,678 Aufrufe • vor 1 Jahr

After a year of intensive research, Dr. William Makis presents the most critical graph of his career: the ivermectin dosing schedule for cancer. According to Dr. Makis, for most cancers - including breast, colon, lung, pancreatic, renal, gastric, and leukemias - a starting dose of 1mg per kg of body weight per day is recommended. For a 60kg individual, this equates to 60mg daily: - Five 12mg pills - Or 6ml of liquid (approx. one teaspoon + 1ml) The evidence for efficacy is compelling and dose-dependent: - Dr. Shankara Chetty saw a prostate cancer patient's PSA drop from 89 to 11 on 45mg/day. - A case from Dr. Tess Lawry showed CA125 (ovarian cancer marker) drop from 288 to 22 on just 0.2mg/kg. - A long-term Castro study on children with leukemia showed no side effects after 6 months at 1mg/kg. For aggressive cancers (pancreatic, brain), the blood-brain barrier may require a higher dose. Dr. Makis cites: - Dr. Landrito's colleague with terminal gallbladder cancer: cancer disappeared after 14 months at 2mg/kg/day. - The highest documented dose is 2.5mg/kg (Dr. Chetty), with only transient visual side effects that resolved. Mainstream oncology will not offer this. Why? Ivermectin is generic, off-patent, and unprofitable. Consequently, there are no funded clinical trials. Dr. Makis's powerful conclusion: "Using ivermectin in cancer is honestly very straightforward. It is a very, very safe drug." His strong suggestion for those struggling: start at 1mg/kg/day. It can be taken for many months, even over a year, with an excellent safety profile based on long-term anecdotal evidence. The power to fight may already be on your shelf.
5:47

After a year of intensive research, Dr. William Makis presents the most critical graph of his career: the ivermectin dosing schedule for cancer. According to Dr. Makis, for most cancers - including breast, colon, lung, pancreatic, renal, gastric, and leukemias - a starting dose of 1mg per kg of body weight per day is recommended. For a 60kg individual, this equates to 60mg daily: - Five 12mg pills - Or 6ml of liquid (approx. one teaspoon + 1ml) The evidence for efficacy is compelling and dose-dependent: - Dr. Shankara Chetty saw a prostate cancer patient's PSA drop from 89 to 11 on 45mg/day. - A case from Dr. Tess Lawry showed CA125 (ovarian cancer marker) drop from 288 to 22 on just 0.2mg/kg. - A long-term Castro study on children with leukemia showed no side effects after 6 months at 1mg/kg. For aggressive cancers (pancreatic, brain), the blood-brain barrier may require a higher dose. Dr. Makis cites: - Dr. Landrito's colleague with terminal gallbladder cancer: cancer disappeared after 14 months at 2mg/kg/day. - The highest documented dose is 2.5mg/kg (Dr. Chetty), with only transient visual side effects that resolved. Mainstream oncology will not offer this. Why? Ivermectin is generic, off-patent, and unprofitable. Consequently, there are no funded clinical trials. Dr. Makis's powerful conclusion: "Using ivermectin in cancer is honestly very straightforward. It is a very, very safe drug." His strong suggestion for those struggling: start at 1mg/kg/day. It can be taken for many months, even over a year, with an excellent safety profile based on long-term anecdotal evidence. The power to fight may already be on your shelf.

Camus

838,106 Aufrufe • vor 11 Monaten

Fenbendazole & Cancer Remission: The Peer-Reviewed Cases Challenging Modern Oncology A peer-reviewed medical publication has delivered a bombshell that the mainstream oncology world cannot ignore. It documents three cases of patients with advanced, metastatic cancer who achieved remarkable remissions after a radical course of action: self-medicating with veterinary-grade medication. The paper details three individuals who were essentially out of conventional options: ➡️ Case 1: An 83-year-old woman with stage 4 breast cancer that had spread to her liver, lungs, and bones. After refusing chemotherapy and entering hospice care, she began a regimen of fenbendazole (a dewormer for dogs), Vitamin D, and multivitamins. By June 2022, her cancer was in complete remission. She has been cancer-free for over three years. ➡️ Case 2: A man with stage 4 prostate cancer and extensive bone metastases. While on standard hormone therapy, he added high-dose fenbendazole and a cocktail of supplements (Vitamin K2, magnesium, melatonin, curcumin). The result? Within 26 months, his cancer growth and spread had completely halted. ➡️ Case 3: A man in his 60s with advanced melanoma, slated for immunotherapy. While waiting for treatment, he began the same fenbendazole and vitamin protocol. By February 2024, before even starting the planned drug, his cancer had completely disappeared. The Critical Nuance Everyone Must Understand: The authors of this paper are NOT advocating for patients to self-medicate with veterinary drugs. The purpose of publishing these cases is precisely the opposite: to sound an alarm. When patients in desperate situations feel compelled to turn to clandestine, unapproved treatments, it is a clear sign that current options are failing them. This paper uses these dramatic "success stories" as a powerful call to action for the scientific community to launch proper clinical trials. The central question is no longer just if cancer metabolism can be targeted, but how we can safely and effectively harness these pathways. The combination of a repurposed drug with foundational lifestyle and nutritional support (the common denominator in all three cases) presents a compelling, albeit unorthodox, avenue for research. This is where the conversation about medical freedom, patient desperation, and scientific rigor collides. It underscores an urgent need to explore all promising pathways, especially those that are patient-driven, with the rigor they deserve. What are your thoughts on the role of repurposed drugs in modern oncology?
9:55

Fenbendazole & Cancer Remission: The Peer-Reviewed Cases Challenging Modern Oncology A peer-reviewed medical publication has delivered a bombshell that the mainstream oncology world cannot ignore. It documents three cases of patients with advanced, metastatic cancer who achieved remarkable remissions after a radical course of action: self-medicating with veterinary-grade medication. The paper details three individuals who were essentially out of conventional options: ➡️ Case 1: An 83-year-old woman with stage 4 breast cancer that had spread to her liver, lungs, and bones. After refusing chemotherapy and entering hospice care, she began a regimen of fenbendazole (a dewormer for dogs), Vitamin D, and multivitamins. By June 2022, her cancer was in complete remission. She has been cancer-free for over three years. ➡️ Case 2: A man with stage 4 prostate cancer and extensive bone metastases. While on standard hormone therapy, he added high-dose fenbendazole and a cocktail of supplements (Vitamin K2, magnesium, melatonin, curcumin). The result? Within 26 months, his cancer growth and spread had completely halted. ➡️ Case 3: A man in his 60s with advanced melanoma, slated for immunotherapy. While waiting for treatment, he began the same fenbendazole and vitamin protocol. By February 2024, before even starting the planned drug, his cancer had completely disappeared. The Critical Nuance Everyone Must Understand: The authors of this paper are NOT advocating for patients to self-medicate with veterinary drugs. The purpose of publishing these cases is precisely the opposite: to sound an alarm. When patients in desperate situations feel compelled to turn to clandestine, unapproved treatments, it is a clear sign that current options are failing them. This paper uses these dramatic "success stories" as a powerful call to action for the scientific community to launch proper clinical trials. The central question is no longer just if cancer metabolism can be targeted, but how we can safely and effectively harness these pathways. The combination of a repurposed drug with foundational lifestyle and nutritional support (the common denominator in all three cases) presents a compelling, albeit unorthodox, avenue for research. This is where the conversation about medical freedom, patient desperation, and scientific rigor collides. It underscores an urgent need to explore all promising pathways, especially those that are patient-driven, with the rigor they deserve. What are your thoughts on the role of repurposed drugs in modern oncology?

Camus

50,224 Aufrufe • vor 8 Monaten

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration
24:40

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 Aufrufe • vor 1 Monat